about
Assembly of Ebola virus matrix protein VP40 is regulated by latch-like properties of N and C terminal tailsOutbreaks of Ebola virus disease in Africa: the beginnings of a tragic sagaMonoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigsEbola virus vaccines: an overview of current approachesPreparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught UsProgress of vaccine and drug development for Ebola preparednessEbola: facing a new transboundary animal disease?A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola VirusEbola virus - from neglected threat to global emergency state.Ebola virus modulates transforming growth factor β signaling and cellular markers of mesenchyme-like transition in hepatocytes.Immune memory to Sudan virus: comparison between two separate disease outbreaks.Virus-like particles activate type I interferon pathways to facilitate post-exposure protection against Ebola virus infection.Harnessing case isolation and ring vaccination to control Ebola.Ebolavirus and Haemorrhagic Syndrome.Ebola Virus: The need to take some preventive measures.Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola VaccineHighly conserved regions in Ebola virus RNA dependent RNA polymerase may be act as a universal novel peptide vaccine target: a computational approachFuture Challenges for Vaccinologists.Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses.Modeling the lifecycle of Ebola virus under biosafety level 2 conditions with virus-like particles containing tetracistronic minigenomes.Knowledge and attitude regarding Ebola virus disease among medical students of Rawalpindi: A preventable threat not yet confrontedTherapeutic potential of the heme oxygenase-1 inducer hemin against Ebola virus infection.Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.Reverse genetics systems as tools for the development of novel therapies against filoviruses.Development of Small-Molecule Antivirals for Ebola.Retracted: Ebola virus: an introduction and its pathology.Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, non-infectious vaccine against Ebola virus challenge in mice.Expression of an immunogenic LTB-based chimeric protein targeting Zaire ebolavirus epitopes from GP1 in plant cells.Epitope-based peptide vaccine design and target site depiction against Ebola viruses: an immunoinformatics study.Reviews of Science for Science Librarians: Ebola Virus Disease
P2860
Q21134356-B73417D8-E21B-4759-B1BA-27B3E8B96A7AQ21245402-AC5E54A2-3150-4471-A03F-CEC71AB149A9Q24604416-3549C3DF-F869-411D-A0CE-4676DA75A30BQ26999232-26DFA830-3035-44BB-8968-9EEFDE2BB091Q28397866-ED345CA5-F827-4F87-BC74-7FB394971934Q30204870-E2849556-9D67-4A74-BDCE-E2BE5D4E0F9EQ30222969-E8DC5515-0AB0-431C-85A5-7BEFF1C63592Q30235073-EB6957D3-6853-49DD-ACA4-1C5B1E8C2134Q30245153-7ADE608A-B508-4A95-99DF-751CF7CDB93DQ34059380-6822A8A4-7352-48EF-BAE0-A303FA413797Q35014908-9FAF77ED-895A-4C6B-BCAE-57801E45854BQ35125834-E3D20A50-D324-4B73-B8FA-2BDCE5513FAFQ35646387-4FBACBA4-B67E-4361-82AE-72E59E41D797Q35670328-3C459D25-00A4-451B-89FE-F5B03D99276AQ35766040-C44567B4-5EEC-4DB6-8974-F225E8B3F5F7Q35917496-90902ACC-AB87-4D2A-975F-8775D427A3B0Q35929274-282EEC10-9BC8-451E-A846-5B702FC078EBQ35989204-E314C08D-8EC3-4F1D-8A40-ED5E600892FEQ36332001-FE6193F9-647C-4C98-801E-0710D351220EQ36788332-3BE1F23B-8100-42E4-9C08-4BC94E9055DCQ37243999-6586FCC0-1608-4F04-ACED-315E68060201Q37607902-80F89DF4-6E9D-4C5F-A858-5FCB7DFBE6B2Q37627897-371E2293-0742-4DDB-8E50-431F3E56A425Q38244444-09E53091-71F8-4BA7-A7ED-5ABA617D1138Q38546746-4BEAEB1C-AFC9-49C7-9664-49D8A98B9A41Q38630575-79E04AA0-3D26-4813-B3B0-B2DC16D4415AQ40052567-716693B8-3D4D-45E5-A0FB-90751BE3A043Q40076985-C8E99B41-5F7C-4F68-A3DC-A3896E6E1196Q40161391-B3B693BF-0BB7-4810-8736-CCFC5E1875E8Q57679718-E95F0048-4560-41F3-926F-FDA64B36347E
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Current ebola vaccines
@ast
Current ebola vaccines
@en
Current ebola vaccines
@en-gb
Current ebola vaccines
@nl
type
label
Current ebola vaccines
@ast
Current ebola vaccines
@en
Current ebola vaccines
@en-gb
Current ebola vaccines
@nl
prefLabel
Current ebola vaccines
@ast
Current ebola vaccines
@en
Current ebola vaccines
@en-gb
Current ebola vaccines
@nl
P2860
P921
P3181
P1476
Current ebola vaccines
@en
P2093
Allison Groseth
P2860
P304
P3181
P356
10.1517/14712598.2012.685152
P407
P577
2012-07-01T00:00:00Z